Assessment
selpercatinib
Adults and adolescents aged 12 years and older with advanced RET-mutated medullary thyroid carcinoma (MTC) requiring systemic therapy after treatment with cabozantinib and/or vandetanib
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations